medigraphic.com
ISSN 1561-3054 (Electronic)

2022, Number 2

<< Back Next >>

Rev Cubana Med Trop 2022; 74 (2)

Risk factors in the development of human immunodeficiency virus associated-lipodystrophy

Rodríguez VEC, Martínez FL

Language: Spanish
References: 33
Page:
PDF size: 458.98 Kb.


ABSTRACT

Introduction: Human immunodeficiency virus associated-lipodystrophy is an important cardiovascular risk factor that develops in 10% to 80% of the cases, impairs quality of life, and reduces adherence to treatment. Its prevention and treatment is of great interest.
Objective: To describe the risk factors that contribute to the development, pathophysiological aspects and treatment of human immunodeficiency virus associated-lipodystrophy.
Methods: A bibliographic search in English and Spanish was conducted. Pubmed, SciELO, Lilacs, Cochrane Library and Web of Science databases were consulted. The search strategy used was: HIV OR AIDS AND lipodystrophy AND adipose tissue AND antiretroviral treatment.
Information, Analysis and Synthesis: Lipodystrophy is characterized by lipoatrophy of the upper and lower limbs, face and buttocks; lipohypertrophy of the visceral, cervical and dorsocervical areas, or a combination of them. Human immunodeficiency virus proteins make modifications in the gene regulation that inhibits the adipocyte differentiation and increases apoptosis, favored by the systemic inflammatory basal state caused by the virus itself. Antiretrovirals play an important role in the genesis of lipodystrophy.
Conclusions: Female sex, malnutrition, and older ages are some of the main risk factors of the human immunodeficiency virus associated-lipodystrophy, which is influenced by the effects of the virus itself and the antiretroviral therapy. An effective drug treatment is not available, only hygienic-dietary measures and aesthetic surgery are considered.


REFERENCES

  1. Koethe JR. Adipose Tissue in HIV Infection. Compre Physiology. 2018 [Acceso 18/10/2021];7(4):1339-57. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1002/cphy.c1600281.

  2. Koethe JR, Heimburger DC. Nutritional aspects of HIV-associated wasting in sub-Saharan Africa. The Am J of Clinic Nutrition. 2010;91(4):1138S-42S. DOI: https://doi.org/10.3945/ajcn.2010.28608D2.

  3. Polo-Rodríguez R, Galindo-Puerto MJ, Martinez-Chamorro E. Documento de Consenso sobre alteraciones metabólicas y riesgo cardiovascular en pacientes con infección por el VIH. Grupo de expertos del Grupo de Estudio sobre Alteraciones Metabólicas (GEAM), de la Secretaría del Plan Nacional sobre el Sida (SPNS) y del Grupo de Estudio de Sida (GeSIDA); 2017 [Acceso 18/10/2021]. Disponible en: Disponible en: https://gesida-seimc.org/wp-content/uploads/2017/02/gesida-guiasclinicas-AlteracionesMetabolicasyRiesgoCV-2020.pdf 3.

  4. WHO. HIV/AIDS. Geneva: WHO; 2021 [Actualizado 17/07/2021; Acceso 18/10/2021]. Disponible en: https://www.who.int/news-room/fact-sheetes/detail/hiv-aids4.

  5. Rabeiro Martínez C, Gil L. Síndrome de lipodistrofia en pacientes con VIH y terapia antirretroviral: aspectos generales. BOLIPK. 2018 [Acceso 18/10/2021];28(49):385. Disponible en: Disponible en: https://www.researchgate.net/publication/329894074 5.

  6. Finkelstein JL, Gala P, Rochford R, Glesby MJ, Mehta S. HIV/AIDS and lipodystrophy: Implications for clinical management in resource-limited settings. J of the Internat Aids Society. 2015 [Acceso 18/10/2021];18(1):19033. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.7448/IAS.18.1.190336.

  7. van Griensven J, De Naeyer L, Mushi T, Ubarijoro S, Gashumba D, Gazille C, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Transac of The Royal Society of Trop Med and Hygiene. 2017;101(8):793-8. DOI: https://doi.org/10.1016/j.trstmh.2007.02.0207.

  8. Pujades-Rodríguez M, Schramm B, Som L, Nerrienet E, Narom P, Chanchhaya N, et al. Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia. Trop Med Int Salud. 2019 [Acceso 18/10/2021];16(2):205-13. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-3156.2010.02689.x

  9. Linares Guerra EM, León Sánchez MA, Santana Porbén S, González Gutiérrez T. Factores relacionados con los cambios longitudinales de la adiposidad corporal en personas con VIH/SIDA. Rev Ciencias Méd Pinar del Río. 2020 [Acceso 18/10/2021];24:4-14. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-31942020000100004&nrm=iso 9.

  10. Tsuda L, da Silva M, Machado A, Fernandes A. Alteraciones corporales: terapia antirretroviral y síndrome de la lipodistrofia en personas que viven con VIH/SIDA. Rev Latino-Am Enfermagem. 2019 [Acceso 18/10/2021];20(5):1-7. Disponible en: Disponible en: https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104-11692012000500005&lng=en&tlng=es 10.

  11. Stanley TL, Grinspoon SK. Body Composition and Metabolic Changes in HIV-Infected Patients. J of Infect Diseases. 2017;205(suppl_3):S383-S90. DOI: https://doi.org/10.1093/infdis/jis20511.

  12. Hsue PY. Mechanisms of Cardiovascular Disease in the Setting of HIV Infection. Canadian J Cardiol. 2019;35(3):238-48. DOI: https://doi.org/10.1016/j.cjca.2018.12.02412.

  13. Powanda MC, Beisel WR. Metabolic Effects of Infection on Protein and Energy Status. J of Nutrition. 2003;133(1):322S-7S. DOI: https://doi.org/10.1093/jn/133.1.322S13.

  14. . Delpierre C, Bonnet E, Marion-Latard F, Aquilina C, Obadia M, Marchou B, et al. Impact of HIV Infection on Total Body Composition in Treatment -Naive Men Evaluated by Dual-Energy X-ray Absorptiometry Comparison of 90 Untreated HIV-Infected Men to 241 Controls. J of Clinic Densitometry. 2007 [Acceso 18/10/2021];10(4):376-80. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S1094695007001990 14.

  15. . Lombardi R, Sambatakou H, Mariolis I, Cokkinos D, Papatheodoridis GV, Tsochatzis EA. Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection. J Digest and Liver Disease. 2016 [Acceso 18/10/2021];48(12):1471-7. Disponible en: https://www.sciencedirect.com/science/article/pii/S1590865816306946

  16. . Macías J, González J, Tural C, Ortega-González E, Pulido F, Rubio R, et al. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. AIDS. 2014 [Acceso 18/10/2021];28(9):1279-87. Disponible en: Disponible en: https://journals.lww.com/aidsonline/Fulltext/2014/06010/Prevalence_and_factors_associated_with_liver.5.aspx 16.

  17. Kosmiski L, Kuritzkes D, Hamilton J, Sharp T, Lichtenstien K, Hill J, et al. Fat distribution is altered in HIV-infected men without clinical evidence of the HIV lipodystrophy syndrome. HIV Medicine 2018 [Acceso 18/10/2021];4(3):235-40. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1468-1293.2003.00151.x17.

  18. Santos APD, Machado DRL, Schwingel A, Chodzko-Zajko WJ, Alves TC, Abdalla PP, et al. Anthropometric cutoff points to identify lipodystrophy characteristics in people living with HIV/AIDS: an observational study. J Nutrición Hospitalaria. 2019 [Acceso 18/10/2021];36:1315-23. Disponible en: Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112019000600014&nrm=iso 18.

  19. Cox Gonzalez de Orbegoso X, Gomez Alvarado A. Importancia del reporte de metodología de Bioimpedancia Eléctrica (BIA) en estudios de composición corporal. J Nutrición Hospitalaria. 2015 [Acceso 18/10/2021];32:959-61. Disponible en: Disponible en: http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112015000800063&nrm=iso 19.

  20. Kuczmarski RJ, Carroll MD, Flegal KM, Troiano RP. Varying Body Mass Index Cutoff Points to Describe Overweight Prevalence Among U. S. Adults: NHANES III (1988 to 1994). 1997 [Acceso 18/10/2021];5(6):542-8. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1002/j.1550-8528.1997.tb00575.x20.

  21. Roubenoff R. Applications of bioelectrical impedance analysis for body composition to epidemiologic studies. The Am J of Clinic Nutrition. 1996;64(3):459S-62S. DOI: https://doi.org/10.1093/ajcn/64.3.459S21.

  22. Visser M, Langlois J, Guralnik JM, Cauley JA, Kronmal RA, Robbins J, et al. High body fatness, but not low fat-free mass, predicts disability in older men and women: the Cardiovascular Health Study. The Am J of Clinic Nutrition. 1998;68(3):584-90. DOI: https://doi.org/10.1093/ajcn/68.3.58422.

  23. . Carr A. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. The Lancet. 2018 [Acceso 18/10/2021];361(9359):726-35. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/pii/S0140673603126566 23.

  24. Aghdassi E, Arendt B, Salit IE, Allard JP. Estimation of Body Fat Mass Using Dual-Energy X-Ray Absorptiometry, Bioelectric Impedance Analysis, and Anthropometry in HIV-Positive Male Subjects Receiving Highly Active Antiretroviral Therapy. JPEN J Parenter Nutrición Enteral. 2017 [Acceso 18/10/2021];31(2):135-41. Disponible en: https://aspenjournals.onlinelibrary.wiley.com/doi/abs/10.1177/014860710703100213524.

  25. Lake JE. The Fat of the Matter: Obesity and Visceral Adiposity in Treated HIV Infection. Current HIV/AIDS Reports. 2017 [Acceso 18/10/2021];14(6):211-9. DOI: https://doi.org/10.1007/s11904-017-0368-625.

  26. Wanjalla CN, McDonnell WJ, Barnett L, Simmons JD, Furch BD, Lima MC, et al. Adipose Tissue in Persons with HIV is Enriched for CD4+ T Effector Memory and T Effector Memory RA+ Cells, which Show Higher CD69 Expression and CD57, CX3CR1, GPR56 Co-expression with Increasing Glucose Intolerance. Front Immunol. 2019 [Acceso 18/10/2021];10(408):1-7. Disponible en: https://www.frontiersin.org/article/10.3389/fimmu.2019.0040826.

  27. Jan V, Cervera P, Maachi M, Baudrimont M, Kim M, Vidal H, et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther. 2018 [Acceso 18/10/2021];9:555-64. Disponible en: Disponible en: https://www.semanticscholar.org/paper/Altered-fat-differentiation-and-adipocytokine-are-Jan-Cervera/bbc2bede3a28ca2c069a299f10e72f0f5d28abf4 27.

  28. . Couturier J, Suliburk JW, Brown JM, Luke DJ, Agarwal N, Yu X, et al. Human adipose tissue as a reservoir for memory CD4+ T cells and HIV. AIDS. 2019 [Acceso 18/10/2021];29(6):667-74. Disponible en: Disponible en: https://journals.lww.com/aidsonline/Fulltext/2015/03270/Human_adipose_tissue_as_a_reservoir_for_memory.4.aspx 28.

  29. . Mercier S, Gueye NFN, Cournil A, Fontbonne A, Copin N, Ndiaye I, et al. Lipodystrophy and Metabolic Disorders in HIV-1-Infected Adults on 4- to 9-Year Antiretroviral Therapy in Senegal: A Case-Control Study. J Adquired Immun Defic Syndrome. 2009 [Acceso 18/10/2021];51(2):224-30. Disponible en: Disponible en: https://journals.lww.com/jaids/Fulltext/2009/06010/Lipodystrophy_and_Metabolic_Disorders_in.17.aspx 29.

  30. Homsanit M, Nelson K, Sonjai A, Anekthananon T, Suwanagool S, Cofrancesco J. Body Shape and Metabolic Abnormalities in Thai HIV-Infected Patients. AIDS Res Human Retroviruses. 2017 [Acceso 18/10/2021];23(11):1314-21. Disponible en: https://www.liebertpub.com/doi/abs/10.1089/aid.2007.001330.

  31. . Gallego-Escuredo JM, Villarroya J, Domingo P, Targarona EM, Alegre M, Domingo JC, et al. Differentially Altered Molecular Signature of Visceral Adipose Tissue in HIV-1-Associated Lipodystrophy. J Adquired Immun Defic Syndrome. 2018 [Acceso 18/10/2021];64(2):142-8. Disponible en: Disponible en: https://journals.lww.com/jaids/Fulltext/2013/10010/Differentially_Altered_Molecular_Signature_of.5.aspx 31.

  32. Mutimura E, Stewart A, Crowther NJ, Yarasheski KE, Cade WT. The effects of exercise training on quality of life in HAART-treated HIV-positive Rwandan subjects with body fat redistribution. Quality of Life Research. 2018;17(3):377. DOI: https://doi.org/10.1007/s11136-008-9319-432.

  33. Schindler K, Rieger A, Tura A, Gmeinhardt B, Touzeau-Römer V, Haider D, et al. The Effect of Rosiglitazone on Insulin Sensitivity, Beta Cell Function, Bone Mineral Density, and Body Composition in HIV-positive Patients on Highly-active Antiretroviral Therapy (HAART). Horm Metab Res. 2019;41(07):573-9. DOI: http://dx.doi.org/10.1055/s-0029-120277933.




2020     |     www.medigraphic.com